Clinical trial
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients…
NCT00260923 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00260923 |
|---|---|
| Title | A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg, 150 mg and 300 mg to Placebo in Patients With Essential Hypertension |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | aliskiren |
| Enrollment | 641 |
| Start date | Nov 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Dec 2, 2005 |
| Last update posted | Nov 8, 2011 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: